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gene, encoding the nuclear bile acid receptor
FXR, with inflammatory bowel disease
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Abstract
Background: Pathogenesis of inflammatory bowel diseases (IBD), ulcerative colitis (UC) and Crohn’s disease (CD),
involves interaction between environmental factors and inappropriate immune responses in the intestine of
genetically predisposed individuals. Bile acids and their nuclear receptor, FXR, regulate inflammatory responses and
barrier function in the intestinal tract.
Methods: We studied the association of five variants (rs3863377, rs7138843, rs56163822, rs35724, rs10860603) of the
NR1H4 gene encoding FXR with IBD. 1138 individuals (591 non-IBD, 203 UC, 344 CD) were genotyped for five
NR1H4 genetic variants with TaqMan SNP Genotyping Assays.
Results: We observed that the NR1H4 SNP rs3863377 is significantly less frequent in IBD cases than in non-IBD
controls (allele frequencies: P = 0.004; wild-type vs. SNP carrier genotype frequencies: P = 0.008), whereas the variant
rs56163822 is less prevalent in non-IBD controls (allele frequencies: P = 0.027; wild-type vs. SNP carrier genotype
frequencies: P = 0.035). The global haplotype distribution between IBD and control patients was significantly
different (P = 0.003). This also held true for the comparison between non-IBD and UC groups (P = 0.004), but not for
the comparison between non-IBD and CD groups (P = 0.079).
Conclusions: We show that genetic variation in FXR is associated with IBD, further emphasizing the link between
bile acid signaling and intestinal inflammation.
Keywords: Bile acid homeostasis, Crohn’s disease, Farnesoid X receptor, Inflammatory bowel disease, Single
nucleotide polymorphisms, Ulcerative colitis
Background
Inflammatory bowel disease (IBD) is a chronic condition
characterized by recurrent inflammation of intestinal
mucosa, and results from aberrant regulation of the mu-
cosal immune system in genetically susceptible indivi-
duals. The etiology of IBD involves a complex
interaction of genetic, environmental, and immunomo-
dulatory factors. Two major forms of chronic mucosal
inflammation have been defined. In Crohn’s disease
(CD), the whole gastrointestinal tract may be affected,
although the most frequent site of inflammation is the
terminal ileum, whereas in ulcerative colitis (UC) the
mucosal inflammation typically affects the colon [1]. For
CD pathogenesis, a strong genetic component has been
suggested by the concordance of 63.6% in monozygotic
twins, but only of 3.6% in dizygotic twins. The concord-
ance of monozygotic twins is lower (6%) in UC, indicat-
ing that genetic susceptibility may play a somewhat
smaller role in this disease [2].
Nuclear receptors are a large family of transcription
factors that are involved in the regulation of numerous
processes, including reproduction, development, and a
wide range of metabolic pathways [3]. The ligand-
dependent activation function at the carboxy-terminus
of most nuclear receptors allows them to sense
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metabolic changes within cells, and orchestrate rapid
transcriptional changes in response [4-6].
The farnesoid X receptor (FXR; gene symbol NR1H4)
is a nuclear receptor that functions as the main sensor
of intracellular bile acid levels [7-9]. The human NR1H4
gene is located on chromosome 12 and is composed of
11 exons and 10 introns [10]. The translation initiation
codon of the NR1H4 gene lies at the 30 end of exon 3,
whereas exons 1 and 2, together with the 50 region of
exon 3, contain the 50 untranslated region (5’-UTR).
Multiple FXR isoforms can be generated via alternative
promoter usage and alternative splicing, and these iso-
forms may have differential transactivation abilities on
specific target promoters [11]. FXR typically acts by
binding to FXR response elements within the target pro-
moters as heterodimers with another member of the nu-
clear receptor family, retinoid X receptor-α (RXRα) [12].
In response to elevated levels of intracellular bile acids,
activated FXR is well known to induce protective gene
expression circuits against bile acid toxicity in the liver
and intestine [13]. Expression of bile acid efflux systems
in ileocytes (organic solute transporter α/β; OSTα/β)
[14,15] and hepatocytes (bile salt export pump; BSEP)
[16-18] is upregulated by bile acid-activated FXR, while
the expression of the respective bile acid uptake systems
apical sodium-dependent bile acid transporter (ASBT)
[19] and Na+-taurocholate cotransporting polypeptide
(NTCP) [20,21] is suppressed by it. FXR also represses
transcription of three genes coding for bile acid synthe-
sizing enzymes, namely cholesterol-7α-hydroxylase
(CYP7A1), sterol-12α-hydroxylase (CYB8B1), and sterol-
27-hydroxylase (CYP27A1) [22,23]. Thus, elevated levels
of bile acids can suppress their own de novo production
through a negative feedback loop involving FXR. In
addition, FXR regulates several genes that can protect
against intestinal inflammation and bacterial overgrowth
[24-26]. Fxr-deficient mice have increased ileal concen-
trations of gut bacteria and exhibit defects in the integ-
rity of the intestinal epithelial barrier. In agreement with
this, the products of a number of genes that are regu-
lated by Fxr in the ileum, including angiogenin (Ang1),
inducible nitric oxide synthase (iNos), and interleukin-18
(Il-18), are known to have antimicrobial actions [26].
Furthermore, it has been reported that reduced expres-
sion of Fxr/FXR is associated with colon inflammation
in rodent models of colitis and in CD patients [25]. Re-
cently, FXR activation was shown to decrease NF-κB-
mediated immune responses and intestinal permeability
in mouse models of colitis [27]. It was subsequently
shown that intestinal inflammation reduces FXR activa-
tion as well as the expression of FXR target genes such
as intestinal bile acid-binding protein (IBABP) and fibro-
blast growth factor 15/19 (FGF15/19) [28]. In agreement
with this, it has been proposed that FXR may contribute
to the resistance of both human and mouse gastric epi-
thelial cells against inflammation-induced injury [29].
The fact that FXR thus appears to play a role in the pro-
tection of the integrity of the intestinal epithelial barrier
and its inverse correlation with the level of intestinal in-
flammation suggest a potential connection between FXR
and the molecular pathogenesis of IBD. FXR variants
have been previously studied in association with several
liver diseases, such as gallstone disease [30], cholangio-
carcinoma [31], intrahepatic cholestasis of pregnancy
[32], and idiopathic infantile cholestasis [33]. Here, we
have investigated five NR1H4 single nucleotide poly-
morphisms - two common SNPs and three rare variants
- which have been previously studied in the context of
human disease, in a well-sized IBD vs. non-IBD cohort,
and report that two of these genetic variants are asso-
ciated with IBD.
Results
Study population
The study population was European and consisted of
more women (806) than men (332). Detailed demo-
graphic data is given in Table 1.
NR1H4 sequence variability
All five NR1H4 variants selected for the study are single
nucleotide substitutions, previously identified within
the NR1H4 gene (www.ncbi.nlm.nih.gov/snp/). Three of
these SNPs can be considered as rare variants:
rs3863377, rs56163822, rs7138843, with reported minor
allele frequencies (MAF) of 4%, 2.2%, and 0.9%, re-
spectively. The other two variants, rs10860603 and
rs35724, are common SNPs, with minor allele frequen-
cies of 20.5% and 40.8% (www.ncbi.nlm.nih.gov/snp/) in
European individuals. The genotype frequencies in all
groups were in Hardy-Weinberg equilibrium (repre-
sented by the χ2 values in Table 2). The obtained allele
and genotype frequencies are given in Tables 3 and 2,
respectively.
Genetic variation in the NR1H4 gene and IBD
The NR1H4 SNP variants rs3863377 and rs56163822
were found to be significantly associated with IBD when
considering an uncorrected significance level of p<0.05.
Table 1 Demographic data of the population included in
the analysis
Characteristics non-IBD IBD CD UC
Population 591 (51.9%) 547 (48.1%) 344 (30.2%) 203 (17.8%)
Mean age (± SD) 55.7 (± 12.6) 42.6 (± 15.1) 40.9 (± 14.9) 45.4 (± 14.9)
Median age 59 41 39 44
Minimum age 20 16 16 18
Maximum age 81 82 79 82
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Upon statistical analysis of the allele (Table 3) and geno-
type (Table 2) frequencies, we observed that the NR1H4
variant rs3863377 is significantly less frequent in IBD
cases than in non-IBD controls (allele frequencies:
P = 0.004; wild-type vs. SNP carrier genotype frequen-
cies: P = 0.008) even when considering an Bonferroni-
corrected significance level of P<0.01. Upon subgrouping
the IBD patients, the significance of the inverse associ-
ation of the rs3863377 SNP remained for the CD
patients when considering an uncorrected significance
level of P<0.05 (allele frequencies: P = 0.015; wild-type
vs. SNP carrier genotype frequencies: P = 0.024), but not
for the UC group (allele frequencies: P = 0.075; wild-type
vs. SNP carrier genotype frequencies: P = 0.083). Con-
versely, the variant rs56163822 is less prevalent in non-
IBD subjects than in IBD patients (allele frequencies:
P = 0.027; wild-type vs. SNP carrier genotype frequen-
cies: P = 0.035); an observation, which is, however, not
significant, when considering a corrected significance
level of P<0.01. Upon subgrouping the patient cohort
according to IBD subtypes, the uncorrected association
remained only significant for the UC group (allele fre-
quencies: P = 0.036; wild-type vs. SNP carrier genotype
frequencies: P = 0.034). Upon adjustment for age and
Table 2 Genotype frequencies of the NR1H4 variants in the study population and the genotype association analysis
SNP rs3863377 (G! A)
WT [GG] Het [GA] Hom [AA] (%) P P’ OR CI χ2
non-IBD 506 (94.4) 28 (5.2) 2 (0.4) 0.14
IBD 438 (97.8) 10 (2.2) 0 0.009** † 0.022* 0.39 0.19-0.80 0.01
CD 271 (97.8) 6 (2.2) 0 0.030* † 0.031* 0.37 0.15-0.191 0.01
UC 167 (97.7) 4 (2.3) 0 0.100 † 0.066 0.40 0.14-1.16 0.01
SNP rs56163822 (−1G ! T)
WT [GG] Het [GT] Horn [TT] (%) P P’ OR CI χ2
non-IBD 560 (96.6) 20 (3.4) 0 0.04
IBD 505 (93.9) 33 (6.1) 1 (0.09) 0.035* 0.451 1.83 1.04-3.23 0.00
CD 319 (94.4) 19 (5.6) 1 (0.09) 0.115 0.846 1.67 0.88-3. 17 0.00
UC 186 (93.0) 14 (7.0) 0 0.034* 0.154 2.11 1.04-4.26 0.13
SNP rs7138843 (A ! T)
WT [AA] Het [AT] Horn [TT] (%) P P’ OR CI χ2
non-IBD 495 (96.7) 17 (3.3) 0 0.03
IBD 417 (95.2) 21 (4.8) 0 0.248 0.772 147 0.76-2.82 0.06
CD 261 (96.0) 11 (4.0) 0 0.369 † 0.612 1.23 0.57-2.66 0.04
UC 156 (94.0) 10 (6.0) 0 0.097 † 0.981 1.87 0.84-4.16 0.10
SNP rs10860603 (G ! A)
WT [GG] Het [GA] Horn [AA] (%) P P’ OR CI χ2
non-IBD 424 (72.8) 143 (24.6) 15 (2.6) 049
IBD 407 (75.8) 121 (22.5) 9 (1.7) 0.261 0.384 0.86 0.66-1.12 0.00
CD 254 (75.4) 76 (22.5) 7 (2.1) 0.403 0.611 0.88 0.65-1.19 0.22
tiC 153 (76.5) 45 (22.5) 2 (1.0) 0.312 0.521 0.82 0.57-1.19 0.43
SNP rs35724 (G! C)
WT [GG] Het [GC] Horn [CC] (%) P P’ OR CI χ2
non-IBD 217 (37.3) 264 (454) 101 (17.3) 1.78
IBD 177 (32.9) 251 (46.7 110 (20.4) 0.125 0.209 1.213 0.95-1.55 1.47
CD 111 (32.8) 155 (45.9) 72 (21.3) 0.175 0.279 1.216 0.92-1.61 1.68
UC 66 (33.0) 96 (48.0) 38 (19.0) 0.277 0.233 1.207 0.86-1.69 0.09
WT, wildtype; Het, heterozygous SNP carrier; Hom, homozygous SNP carrier.
χ2, χ2-values of Hardy-Weinberg equilibrium.
χ2 tests were carried out considering hetero- and homozygous SNP carriers as one group in case and control populations; except that Fisher’s exact test was used
when the cell count was 10 or less (†).
*, P<0.05; **, P<0.01.
OR, odds ratio; CI, confidence interval.
P’, P value adjusted to age and gender.
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gender, the uncorrected significance (P<0.05) of geno-
type frequency association with IBD remained for
rs3863377, but was reduced to P>0.05 for rs56163822.
There were no significant differences in the allele fre-
quency distribution between the subject groups for
NR1H4 variants rs7138843, rs10860603, and rs35724.
NR1H4 haplotype analysis
All individuals, for whom genotype determination could
be performed for all five NR1H4 SNPs under study were
included in the haplotype prediction analyses. Four hun-
dred and eighty-six non-IBD cases, along with 243 CD
patients and 150 UC patients were thus haplotyped.
Twenty haplotypes and up to thirty-nine diplotypes were
predicted by the software FAMHAP to exist in the stud-
ied cohort. NR1H4 haplotypes were significantly differ-
entially distributed in the IBD and control groups
(Table 4, P = 0.003) upon global haplotype distribution
analysis. This observation held partially true upon strati-
fication according to disease subtype. Here, the haplo-
type frequencies differ significantly between the UC
patients and the non-IBD control group (Table 5,
P = 0.004), but not between the CD patients and the con-
trol subjects (Table 6, P = 0.079). We particularly note
Table 3 Allele frequencies of the NR1H4 variants in the study population and the allele association analysis
SNP rs3863377 (G ! A)
Case MAF (%) P OR CI Reported MAFs1
non-IBD 32 (2.9) 4.0%
IBD 10 (1.1) 0.004** † 0.37 0.18-0-75
CD 6 (1.1) 0.015* † 0.36 0.15-0.86
UC 4 (1.2) 0.075 † 0.38 0.14-1.10
SNP rs56163822, (G !T)
Case MAF (%) P OR CI Reported MAFs1
non-IBD 20 (1.7) 2.2%
IBD 34 (3.2) 0.027* 1.86 1.06-3.25
CD 20 (2.9) 0.081 1.74 0.93-3.25
UC 14 (3.5) 0.036* 2.07 1.03-4.13
SNP rs7138843, (A ! T)
Case MAF (%) P Reported MAFs1
non-IBD 17 (1.7) 0.9%
IBD 21 (2.4) ns
CD 11 (2.0) ns
UC 10 (3.0) ns †
SNP rs10860603, (G ! A)
Case MAF (%) P Reported MAFs1
non-IBD 173 (14.9) 20.5%
IBD 139 (12.9) ns
CD 90 (13.4) ns
UC 49 (12.3) ns
SNP rs35724, (G ! C)
Case MAF (%) P Reported MAFs1
non-IBD 466 (40.0) 40.8%
IBD 471 (43.8) ns
CD 299 (44.4) ns
UC 172 (43.0) ns
MAF, minor allele frequencies.
1According to the National Center for Biotechnology Information (NCBI) SNP database.
Chi-square (χ2) test was used to determine statistical significance, except that Fisher’s exact test was used when the cell count was 10 or less (†).
*, P<0.05; **, P<0.01.
P’, P value adjusted to age and gender.
OR, odds ratio; CI, confidence interval.
ns, not significant.
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Table 4 Haplotype analysis of IBD patients and non-IBD controls
Order Haplotype
a) b) c) d) e)
Cases (%) Controls (%) OR (C.I.) P Order Haplotype
a) b) c) d) e)
Cases (%) Controls (%) OR (C.I.) P
1 G G A G G 405.9 (52.2) 510.1 (52.6) 0.98 (0.81-1.19) 1 G G A G G 417 (53.6) 530 (54.6) 0.96 (0.79-1.16) a) ns
2 G G A G C 243.9 (31.3) 261 (26.9) 1.24 (1.01-1.53) 0.064 2 G G A G C 235 (30.2) 241 (24.7) 1.31 (1.06-1.62) a) 0.012
3 G G A A C 55.9 (7.2) 91.3 (9.4) 0.75 (0.53-1.05) 0.091 3 G G A A C 63 (8.1) 108 (11.1) 0.7 (0.51-0.97) a) 0.03
4 G G A A G 27.4 (3.5) 47.5 (4.9) 0.71 (0.44-1.14) 4 G G A A G 18 (2.3) 31 (3.2) 0.72 (0.40-1.29) a) ns
5 A G A G G 2.7 (0.4) 13.4 (1.4) 0.25 (0.07-0.93) 0.017 5 A G A G G 2 (0.3) 13 (1.3) 0.19 (0.04-0.84) 0.017
6 A G A G C 6.6 (0.8) 12 (1.2) 0.68 (0.26-1.76) 6 A G A G C 8 (1.0) 14 (1.4) 0.71 (0.30-1.70) ns
7 G G T G C 5 (0.6) 9.1 (0.9) 0.68 (0.23-2.04) 7 G G T G C 4 (0.5) 9 (0.9) 0.55 (0.17-1.80) ns
8 G T A G G 3.8 (0.5) 7.5 (0.8) 0.63 (0.18-2.17) NA 8 G T A G G 2 (0.3) 7 (0.7) 0.35 (0.07-1.71) ns
9 G T A G C 10.4 (1.3) 5.7 (0.6) 2.27 (0.82-6.32) 0.090 9 G T A G C 12 (1.5) 6 (0.6) 2.52 (0.94-6.74) ns
10 G G T G G 2 (0.3) 3.1 (0.3) 0.79 (0.13-4.70) NA 10 G G T G G 1 (0.1) 2 (0.2) 0.62 (0.06-6.89) ns
11 G T A A G 0.8 (0.1) 1.8 (0.2) NA NA 11 G T A A G 1 (0.1) 2 (0.2) 0.63 (0.06-6.89) ns
12 A G A A G 0.2 (0) 2.0 (0.2) 0.13 (0–11.93) NA 12 A G A A G 0 1 (0.1) NA ns
13 G G T A C 2.4 (0.3) 2.3 (0.2) 1.29 (0.21-7.99) NA 13 G G T A C 4 (0.5) 4 (0.4) 1.25 (0.31-5.00) ns
14 G T T G C 7.4 (1) 1.0 (0.1) NA NA 14 G T T G C 7 (0.9) 1 (0.1) 8.80 (1.08-71.70) 0.026
15 G G T A G 1.1 (0.1) 0.5 (0.1) NA NA 15 G G T A G 1 (0.1) 0 NA ns
16 G T T A G 1.2 (0.2) 1.0 (0.1) NA NA 16 G T T A G 3 (0.4) 1 (0.1) 3.75 (0.39-36.15) ns
17 A G A A C 0.1 (0) 0.6 (0.1) NA NA 17 A G A A C 0 0 NA NA
18 A T A G C 0.4 (0.1) 0 (0) NA NA 18 A T A G C 0 0 NA NA
19 G T T A C 1 (0.1) 0 (0) NA NA 19 G T T A C 0 0 NA NA
389 cases (778 haplotypes) and 485 controls (970 haplotypes) were included in the analysis.
Global haplotype distribution: P = 0.003.
Left table side: Predicted haplotypes obtained with Monte Carlo simulations using FAMHAP. The calculation of odds ratios and a global P value for haplotype distribution was performed on these results using
FAMHAP. The haplotype order follows a priority ranking within the control group. Nineteen haplotypes were predicted. The haplotype base positions correspond to a) rs3863377, b) rs56163822, c) rs7138843, d)
rs10860603, and e) rs35724. As FAMHAP tested all haplotypes with a frequency >0.01, the frequency distribution of eight haplotypes (1–7, 9) was included. Relevant P-values for four haplotypes were displayed by
FAMHAP. None of the individual haplotypes are significantly differentially distributed between the IBD and control groups.
OR, odds ratio; NA, not applicable, FAMHAP did not calculate an odds ratio on these results because of a low haplotype frequency value predicted.
Right table side (italics): Most likely occurring haplotype frequencies (haplotype in best reconstruction) predicted by FAMHAP. Based on these predictions significance tests were performed. P-values were calculated
using the Fisher’s exact test or (if marked with a) ) using the Chi-Square test. A Bonferroni-corrected P-value of 0.003 (19 tests) was taken as significance level. According to this, none of the haplotypes appeard to be
significantly differently distributed between the case and control groups.
OR, odds ratio; C.I., confidence interval; NA, OR not applicable because of at least one cell count with the value of null; ns, not significant and P >0.05.
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Table 5 Haplotype analysis of UC patients and non-IBD controls
Order Haplotype
a) b) c) d) e)
Cases (%) Controls (%) OR (C.I.) P Order Haplotype
a) b) c) d) e)
Cases (%) Controls (%) OR (C.I.) P
1 G G A G G 146.6 (49.5) 507.5 (52.3) 0.89 (0.69-1.16) 1 G G A G G 153 (51.7) 530 (54.6) 0.89 (0.68-1.15) a) ns
2 G G A G C 98.8 (33.4) 263.9 (27.2) 1.34 (1.01-1.77) 0.022 2 G G A G C 94 (31.8) 239 (24.6) 1.42 (1.07-1.89) a) 0.015
3 G G A A C 16.9 (5.7) 89.5 (9.2) 0.59 (0.35-1.02) 0.010 3 G G A A C 21 (7.1) 111 (11.4) 0.59 (0.36-0.96) a) 0.038
4 G G A A G 14.2 (4.8) 49 (5.1) 0.95 (0.52-1.73) 4 G G A A G 9 (3) 30 (3.1) 0.98 (0.46-2.09) a) ns
5 A G A G G 1.2 (0.4) 14.1 (1.5) 0.28 (0.04-1.79) 0.110 5 A G A G G 1 (0.3) 13 (1.3) 0.25 (0.03-1.91) ns
6 A G A G C 1.7 (0.6) 11 (1.1) 0.5 (0.10-2.53) 6 A G A G C 2 (0.7) 14 (1.4) 0.46 (0.10-2.06) ns
7 G G T G C 1.6 (0.5) 9.4 (1) 0.54 (0.10-2.97) 7 G G T G C 1 (0.3) 11 (1.1) 0.30 (0.04-2.30) ns
8 G T A G G 2.2 (0.7) 7.8 (0.8) 0.92 (0.21-4.13) NA 8 G T A G G 1 (0.3) 7 (0.7) 0.47 (0.06-3.81) ns
9 G T A G C 2.6 (0.9) 5.4 (0.6) 1.58 (0.36-6.99) NA 9 G T A G C 3 (1) 6 (0.6) 1.65 (0.41-6.62) ns
10 G G T G G 0.3 (0.1) 3.0 (0.3) 0.37 (0.01-13.09) NA 10 G G T G G 0 2 (0.2) NA ns
11 G T A A G 0.8 (0.3) 1.8 (0.2) NA NA 11 G T A A G 1 (0.3) 2 (0.2) 1.64 (0.15-18.17) ns
12 A G A A G 0.2 (0.1) 2.0 (0.2) 0.33 (0-30.58) NA 12 A G A A G 0 1 (0.1) NA ns
13 G G T A C 1.1 (0.4) 2.0 (0.2) 1.83 (0.18-18.47) NA 13 G G T A C 2 (0.7) 1 (0.1) 6.59 (0.60-73.0) ns
14 G T T G C 4.4 (1.5) 1.0 (0.1) NA 0.005* 14 G T T G C 4 (1.4) 1 (0.1) 13.27 (1.48-119.30) 0.012
15 G G T A G 1.3 (0.4) 0.7 (0.1) NA NA 15 G G T A G 1 (0.3) 1 (0.1) 3.29 (0.20-52.71) ns
16 G T T A G 1.2 (0.4) 1.0 (0.1) NA NA 16 G T T A G 2 (0.7) 1 (0.1) 6.59 (0.60-73.00) ns
17 A G A A C 0.2 (0.1) 0.9 (0.1) NA NA 17 A G A A C 0 0 NA NA
18 A T A G C 0.7 (0.2) 0 NA NA 18 A T A G C 1 (0.3) 0 NA ns
19 G T T A C 0.2 (0.1) 0 NA NA 19 G T T A C 0 0 NA NA
148 cases (296 haplotypes) and controls 485 (970 haplotypes) were included in the analysis.
Global haplotype distribution: P=0.004.
Left table side: Predicted haplotype frequencies obtained with Monte Carlo simulations using FAMHAP: The calculation of odds ratios and a global P-value for haplotype distribution was performed on these results
using FAMHAP. The haplotype order follows a priority ranking within the control group. Nineteen haplotypes were predicted. The haplotype base positions correspond to a) rs3863377, b) rs56163822, c) rs7138843, d)
rs10860603, and e) rs35724. As FAMHAP tested all haplotypes with a frequency >0.01, the frequency distribution of eight haplotypes (1-7, 14) was included. Relevant P-values for four haplotypes were displayed by
FAMHAP. One single haplotype (14) was significantly differentially distributed between the UC and control groups. OR, odds ratio; NA, not applicable, FAMHAP did not calculate an odds ratio on these results because
of a low haplotype frequency value predicted.
Right table side (italics): Most likely occurring haplotype frequencies (haplotypes in best reconstruction) predicted by FAMHAP. Based on these predictions significance tests were performed. P-values were calculated
using the Fisher’s exact test or (if marked with a) ) the Chi-Square-test. A Bonferroni-corrected P-value of 0.003 (19 tests) was taken as significance level. According to this, none of the haplotypes appeared to be
significantly different distributed between the UC and control groups. OR, odds ratio; C.I., confidence interval; NA, OR not applicable because of at least one cell count with the value of null; ns, not significant
and P > 0.05.
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Table 6 Haplotype analysis of CD patients and non-IBD controls
Order Haplotype
a) b) c) d) e)
Cases (%) Controls (%) OR (C.I.) P Order Haplotype
a) b) c) d) e)
Cases (%) Controls (%) OR (C.I.) P
1 G G A G G 258.6 (53.6) 511.2 (52.7) 1.04 (0.83-1.29) 1 G G A G G 265 (55.5) 530 (55.3) 1.01 (0.81-1.26) a) ns
2 G G A G C 146.8 (30.5) 259.0 (26.7) 1.20 (0.95-1.53) 2 G G A G C 140 (29.4) 239 (24.9) 1.25 (0.98-1.60) a) ns
3 G G A A C 39.3 (8.2) 93.9 (9.7) 0.83 (0.56-1.22) 3 G G A A C 44 (9.2) 110 (11.5) 0.79 (0.54-1.14) a) ns
4 G G A A G 13 (2.7) 45.9 (4.7) 0.56 (0.30-1.04) 0.062 4 G G A A G 9 (1.9) 31 (3.2) 0.58 (0.27-1.22) ns
5 A G A G G 2.1 (0.4) 14.4 (1.5) 0.29 (0.07-1.24) 0.053 5 A G A G G 1 (0.2) 13 (1.4) 0.15 (0.02-1.17) 0.044
6 A G A G C 3.9 (0.8) 11.6 (1.2) 0.68 (0.22-2.15) 6 A G A G C 5 (1) 14 (1.5) 0.72 (0.26-2.00) ns
7 G G T G C 3.8 (0.8) 9.4 (1.0) 0.81 (0.24-2.68) 7 G G T G C 5 11 0.91 (0.32-2.65) ns
8 G T A G G 2.1 (0.4) 7.8 (0.8) 0.53 (0.11-2.49) NA 8 G T A G G 1 (0.2) 7 (0.7) 0.29 (0.04-2.33) ns
9 G T A G C 6.1 (1.3) 5.7 (0.6) 2.19 (0.70-6.91) 0.122 9 G T A G C 7 (1.5) 6 (0.6) 2.37 (0.79-7.09) ns
10 G G T G G 1.5 (0.3) 3.1 (0.3) 0.98 (0.14-6.86) NA 10 G G T G G 1 (0.2) 2 (0.2) 1.01 (0.09-11.13) ns
11 G T A A G 0 1.6 (0.2) NA NA 11 G T A A G 0 2 (0.2) NA ns
12 A G A A G 0 2.1 (0.2) NA NA 12 A G A A G 0 1 (0.1) NA ns
13 G G T A C 0.9 (0.2) 2.5 (0.3) 0.73 (0.07-7.9) NA 13 G G T A C 0 2 (0.2) NA ns
14 G T T G C 3.1 (0.6) 0.9 (0.1) NA NA 14 G T T G C 3 (0.6) 1 (0.1) 6.07 (0.63-58.53) ns
15 G G T A G NA NA NA NA 15 G G T A G 0 0 NA NA
16 G T T A G 0.7 (0.1) 1.0 (0.1) NA NA 16 G T T A G 1 (0.2) 1 (0.1) 2.02 (0.13-32.30) ns
17 A G A A C NA NA NA NA 17 A G A A C 0 0 NA NA
18 A T A G C NA NA NA NA 18 A T A G C 0 0 NA NA
19 G T T A C NA NA NA NA 19 G T T A C 0 0 NA NA
241 cases (482 haplotypes) and 485 controls (970 haplotypes) were included in the analysis.
Global haplotype distribution: P=0.079.
Left table side: Predicted haplotype frequencies obtained with Monte Carlo simulations using FAMHAP: The calculation of odds ratios and a global P-value for haplotype distribution was performed on these results
using FAMHAP. The haplotype order follows a priority ranking within the control group. Nineteen haplotypes were predicted. The haplotype base positions correspond to a) rs3863377, b) rs56163822, c) rs7138843, d)
rs10860603, and e) rs35724. As FAMHAP tested all haplotypes with a frequency >0.01, the frequency distribution of eight haplotypes (1-7, 9) was included. Relevant P-values for three haplotypes were displayed by
FAMHAP. None of the individual haplotypes are significantly differentially distributed between the CD and control groups. OR, odds ratio; NA, not applicable, FAMHAP did not calculate an odds ratio on these results
because of a low haplotype frequency value predicted.
Right table side (italics): Most likely occurring haplotype frequencies (haplotypes in best reconstruction) predicted by FAMHAP. Based on these predictions significance tests were performed.
P-values were calculated using the Fisher’s exact test or (if marked with a) ) the Chi-Square-test. A Bonferroni-corrected P-value of 0.003 (19 tests) was taken as significance level. According to this, none of the
haplotypes appeared to be significantly different distributed between the CD and control groups.
OR, odds ratio; C.I., confidence interval; NA, OR not applicable because of at least one cell count with the value of null; ns, not significant and P > 0.05.
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that the haplotype 14, GTTGC, is predicted to occur sig-
nificantly (P = 0.005) more frequently in the UC group in
comparison with the non-IBD cohort. This haplotype
harbours the more frequent allele G at the first SNP
position rs3863377, which was shown to be significantly
associated with IBD even after Bonferroni correction. It
is thus a possible risk haplotype for the development of
IBD, although we note that the overall frequency for this
haplotype is rather low. Upon best reconstruction ana-
lysis the significance of the association of the haplotype
14, GTTGC, with the UC group was, however, lost
(P=0.012) (Table 5, italicized section). No significant
associations were observed for the predicted diplotype
patterns and IBD (data not shown). As shown in the LD
plot (Figure 1), there was no significant linkage disequi-
librium between any of the five NR1H4 SNPs studied.
Discussion
The complex pathophysiology of IBD still remains
largely unelucidated, although multiple factors, both
genetic and environmental, are clearly involved. SNPs
and mutations within several genes have been proposed
to be associated with the risk to develop IBD. Prior
studies have revealed more than 70 genes that are poten-
tially associated with IBD [34,35]. The region on
chromosome 16q11-12 named IBD1 was identified in
1996, and the fine mapping of this region led to the
identification of the NOD2 (nucleotide-binding
oligomerization domain 2)/CARD15 (caspase activation
recruitment domain 15) genes [36,37], and a member of
a family of pattern recognition receptors (PRRs) that
recognizes microbial components and modifies inflam-
matory responses to bacterial triggers such as lipopoly-
saccharides (LPS), through the activation of NF-κB
[38,39]. Furthermore, genes that play roles in immuno-
logical cell-cell interactions and signaling, such as the
tumor necrosis factor receptor 1 (TNFR1) [40], the
interleukin-23 receptor (IL23R) [41], and other genes
that are involved in immune response to bacteria, such
as the toll-like receptor 4 (TLR4) [42,43], have been pro-
posed to be associated with IBD. In addition, regulatory
genes, such as the protein tyrosine phosphatase N2
(PTPN2) [44,45] and the anti-inflammatory nuclear
receptor peroxisome proliferator-activated receptor-γ
(PPARγ) [46], as well as genes encoding membrane
transporters multidrug resistance gene 1 (MDR1)
[47-49] and the organic cation transporter 1/2 (OCTN1/
2) [47,50] have been proposed to be associated with the
risk of chronic mucosal inflammation.
In this report, we describe the identification of single
nucleotide polymorphisms associated with the diagnosis
of IBD within the NR1H4 gene, encoding the nuclear re-
ceptor for bile acids, FXR, in a well-sized European co-
hort. Five NR1H4 SNPs were analyzed, all of which have
previously been studied in the context of other human
disease conditions: rs3863377, rs7138843, rs56163822,
rs35724, and rs10860603. The NR1H4 variants
rs7138843 and rs56163822 have been previously shown
to be inversely associated with cholelithiasis in a
Mexican population and may thus play a protective role
in gallstone disease, while the variant rs3863377 showed
no association with cholelithiasis [51]. The variant
rs56163822 was found to be more common in a British
control group than in patients with intrahepatic choles-
tasis of pregnancy (ICP), although this difference did not
reach statistical significance [32]. NR1H4 variants
rs35724 and rs10860603 have been previously shown to
be significantly associated with elevated body mass index
and obesity [52]. IBD is often associated with hepatobili-
ary manifestations, [53,54] implying that the etiology of
the diseases affecting the two organs, intestine and liver,
may have common factors, also supported by our find-
ings that the same NR1H4 genetic variants may be asso-
ciated with both.
The variant rs3863377 is located in the 5’ region of the
NR1H4 gene, whereas the rs7138843 lies within the
NR1H4 intron 7 and variants rs35724 and rs10860603
Figure 1 Pairwise linkage disequilibrium calculations between
the five NR1H4 SNPs under study in the non-IBD population. A
plot with D’ values; Colour scheme: D’< 1 and LOD< 2, white, D’= 1
and LOD< 2, blue, D’< 1 and LOD≥ 2, pink.
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within NR1H4 intron 9. In none of these cases is it
known, how the presence of the SNP may affect the ex-
pression and/or molecular function of FXR. As the SNP
rs3863377 is located within the 5’ region, it may alter a
binding site for a transcription factor and may thus
affect NR1H4 gene expression. The intronic SNPs
rs7138843, rs10860603, and rs35724 could potentially in-
fluence splicing of the FXR mRNA. The substitution
-1 G>T in rs56163822 lies in the base position adjacent
to the translation initiation site, and was shown to lead
to reduced FXR protein expression and decreased level
of FXR-dependent promoter activation in human embry-
onic kidney cells. In another study the functional activity
of the -1 G>T variant also appeared to be compromised,
although transcriptional and translational efficiencies of
the variant appeared comparable to the wild-type in cell-
free assays and in HeLa cells [55]. Interestingly, the
mRNA expression levels of the FXR target genes SHP
and OATP1B3 are significantly reduced in the livers of
the carriers of the rs56163822 allele, while the FXR
mRNA expression level remains comparable, further in-
dicating that this polymorphism may rather lead to wea-
kened function than to reduced expression level of FXR.
In our current genotyping analysis we have found that
for the NR1H4 variant rs3863377, the IBD population
has a significantly lower frequency of carriers of the
rarer allele than the healthy population, suggesting that
this 5’ region SNP may confer a protective effect against
the disease. In the case of the rs56163822 NR1H4 vari-
ant, the rare allele is significantly more prevalent in the
IBD population, suggesting that previously reported
reduced FXR function exhibited by this variant may con-
tribute to IBD pathogenesis. In the case of the rare
NR1H4 variant under study, rs7138843, and the com-
mon SNPs rs10860603 and rs35724, no significant differ-
ences between the study populations were observed. In
agreement with the associations observed for two of the
five single SNP variants, the predicted global haplotype
pattern was significantly different in IBD patients and
non-IBD controls.
In our study, five NR1H4 SNPs were investigated. Dur-
ing the preparation of our manuscript, Nijmeijer et al.
[56] published a study showing that mRNA expression
of FXR and its target gene SHP are decreased in the
ileum of Crohn’s disease patients, in further support of
the importance of the role for FXR in IBD. These
authors also studied potential association of nine NR1H4
SNPs with IBD in a Dutch population, but did not dis-
cover any associations that remained significant upon
correction for multiple testing. We note that in their
analysis Nijmeijer et al. did not include the SNP
rs3863377, the inverse association by which with IBD
remained significant even after Bonferroni correction in
the current study. As numerous further polymorphisms
are known to exist in the NR1H4 gene (www.ncbi.nlm.
nih.gov/snp/), our report, as well as that by Nijmeijer
et al., serve as initial characterizations of the role of FXR
genetic variants in IBD. Furthermore, these findings war-
rant further studies into genetic variants in the NR1H4
gene in the context of other inflammatory conditions
affecting further tissues that express FXR.
FXR ligands, such as the hydrophilic bile acid urso-
deoxycholic acid, have been proposed as attractive
options for the therapy of liver diseases, such as chole-
static disease and non-alcoholic fatty liver disease [57].
Our finding that FXR genetic variants are associated
with IBD, together with prior observations on FXR ex-
pression being altered in Crohn’s disease [56] and on
FXR promoting intestinal barrier integrity [27] and anti-
bacterial defence [26], further emphasizes the potential
benefits of FXR ligand administration also in IBD. We
further speculate that testing for genetic variation in the
NR1H4 gene may contribute to the early IBD diagnosis
and prediction of therapy response in the future.
Conclusions
In conclusion, our results further support the role for
FXR as a modulator of intestinal inflammation and as an
important player in enteroprotection. The link between
the bile acid receptor FXR and IBD also further empha-
sizes the potential importance of bile acid homeostasis
and metabolism in the pathogenesis of IBD.
Methods
Study subjects
The study population was European, and comprised of
591 healthy subjects and 547 IBD patients, from which
203 were diagnosed to suffer from UC and 334 from
CD. The IBD subjects were recruited at the centers par-
ticipating in the Swiss Inflammatory Bowel Disease Co-
hort Study (SIBDCS) [58]. For the IBD patients, the
diagnosis of UC or CD was confirmed by the study
investigators based on clinical presentation, endoscopic
findings, and histology. Non-IBD controls were recruited
from gastroenterological patients undergoing surveil-
lance colonoscopy, and showed no symptoms of IBD.
History of colorectal cancer was used as an exclusion
criterion for both IBD patients and non-IBD controls.
All subjects provided their written informed consent to
be included in the study. Ethical approvals were obtained
from the local medical ethical committees of all study
sites involved in the study: 1) The Swiss IBD Cohort
Study (SIBDCS) (the participating centers are listed in
http://ibdcohort.ch/index.php?id = 94&L= 2; ethical li-
cense EK-1316). 2) The Bioethical Committee at the
Maria Sklodowska-Curie Memorial Cancer Centre and
Institute of Oncology, Warsaw, Poland (ethical licenses
25/2006 and 25/2006/2007).
Attinkara et al. BMC Research Notes 2012, 5:461 Page 9 of 12
http://www.biomedcentral.com/1756-0500/5/461
DNA extraction
Genomic DNAs were extracted from either EDTA-blood
or intestinal biopsies using the QIAamp DNA Mini Kit
(QIAGEN, Hombrechtikon, Switzerland) or the TRIzol
reagent (Invitrogen, Basel, Switzerland), respectively,
according to the manufacturer’s instructions. The gen-
omic DNAs were quantified with a NanoDrop ND-1000
spectrophotometer (NanoDrop Technologies, Wilming-
ton, DE) and diluted to a final concentration of 10 ng/μl.
Genotyping of NR1H4 single nucleotide polymorphisms
Genotyping of the five NR1H4 SNPs was performed
using TaqMan allelic discrimination assays. The cycling
was performed on an 7900HT Fast Real-Time PCR
system (Applied Biosystems, Rotkreuz, Switzerland) by
using the inventoried TaqMan SNP Genotyping
Assays C_28000279_10, C_25598395, C_25598386_10,
C_2366616_10, C_2800610_10 for the SNPs rs3863377,
rs7138843, rs56163822, rs35724, and rs1086060, respect-
ively. Twenty nanograms of each genomic DNA was used
per PCR reaction in a volume of 5 μl. The amplification
run conditions were: Once 50°C for 2 min, once 95°C for
10 min, 45 times 95°C for 15 sec, and 60°C for 1 min.
Statistical analysis
Statistical analysis for the individual SNP associations
was performed using the software package SPSS 18
(SPSS Inc., Chicago, IL). The Chi-square test or Fisher’s
exact test were used to determine associations between
individual SNPs and subject phenotypes. A P-value of
<0.05 was considered as significant in non-corrected
statistical tests and of <0.01 after correction for multiple
testing for the five SNPs (according to Bonferroni). The
software package PSPower (http://biostat.mc.vanderbilt.
edu/twiki/bin/view/Main/PowerSampleSize) was used
for retrospective power calculations. A retrospective
power analysis of the applied statistical tests on genotype
distributions revealed a power of 0.525 for the SNP
rs3863377 and a power of 0.323 for the SNP rs56163822,
when considering a Bonferroni-corrected alpha level of
0.01 and the detected ORs as shown in Table 2 for the
applied χ2-tests. Linkage disequilibria (LD) were calcu-
lated using D’ statistics and the software package Haplo-
view (www.haploview.com). Haplotype predictions and
frequency estimations were performed using the soft-
ware tool FAMHAP (www.famhap.meb.uni-bonn.de).
FAMHAP performs a permutation test on associations
between estimated haplotypes and the affection state
based on Monte Carlo simulations. The expectation
maximization (EM) algorithm was used to obtain
maximum-likelihood estimates of the haplotype frequen-
cies of the sample composed of cases and controls. Indi-
viduals with several possible haplotype explanations are
assigned with a likelihood weight to each possible
haplotype and its calculated frequency estimate. A con-
tingency table is constructed summing up all individuals’
weighted haplotype explanations for each haplotype and
the chi-square statistics computed. The corresponding
P-value is assessed via Monte Carlo simulation, i.e. in
each replication of the algorithm a sample composed of
a subgroup of case and control samples is randomly
drawn and permuted. FAMHAP implements the calcula-
tion of the global P-value via Monte Carlo simulations,
as the cell counts used in the contingency table are
based on haplotype frequency estimates with increased
variances, not on real haplotype counts, which, as a re-
sult, does not necessarily follow exactly a chi-square dis-
tribution [59,60]. A value of P<0.05 was considered to be
significant. Bonferroni-corrected P-values (P<0.006, cor-
rected for eight haplotypes that FAMHAP considered to
be relevant to test for) were defined as the significance
level for single haplotype comparisons in the white sec-
tions of Tables 4-6. In addition, haplotypes in best re-
construction (not weighted) were listed for the case and
control groups in Tables 4-6 (grey sections) and used for
association analysis performing Fisher’s exact tests or, in
case of high cell counts (11 or more), Chi-square tests.
Bonferroni-corrected significance levels (p<0.003, cor-
rected for 19 haplotypes) were used for significance
testing.
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